Steadcast
The Top Line cover art

The Top Line

Fierce Life Sciences

Fierce Biotech and Pharma journalists break down weekly biopharma and medtech business news.

Why we picked this

We picked The Top Line for its no-nonsense weekly accounting of biopharma and medtech business. Three Fierce journalists track mergers, R&D pipelines, and regulatory shifts with a practitioner’s eye for how policy hits the income statement. The show trades hype for operational specifics—supply-chain margins, tariff exposure, the capital consequences of drug-pricing reform. Listeners who want industry logic, not health-technology boosterism, will find the feed earns its weekly slot.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.

HealthBusiness12 episodes on Steadcast · Latest Jul 2026

Recent episodes

GSK’s first lung cancer approval, a new IPO path and more

Jul 24, 202611 min

Why modern clinical trials need a finance-first strategy (Sponsored)

Jul 20, 202617 min

5 emerging biotech hubs

Jul 17, 202624 min

Decision readiness is the next AI advantage (Sponsored)

Jul 13, 202618 min

A $10B deal, China trial scrutiny and highlights from ADA 2026

Jul 10, 202624 min

The deal before the deal

Jun 26, 202641 min

FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)

Jun 16, 202620 min

Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones

Jun 12, 202615 min

Why MRD is becoming central to oncology drug development (Sponsored)

Jun 10, 202618 min

Behind the headlines of ASCO 2026

Jun 5, 202629 min

Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)

Jun 3, 202621 min

Boston, China and the future of biotech

May 29, 202635 min

Related shows